Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.
Pellicelli AM, Romano M, Stroffolini T, Mazzoni E, Mecenate F, Monarca R, Picardi A, Bonaventura ME, Mastropietro C, Vignally P, Andreoli A, Marignani M, D'Ambrosio C, Miglioresi L, Nosotti L, Mitidieri O, Gentilucci UV, Puoti C, Barbaro G, Barlattani A, Furlan C, Barbarini G; CLEO Group. Pellicelli AM, et al. Among authors: bonaventura me. BMC Gastroenterol. 2012 Nov 16;12:162. doi: 10.1186/1471-230X-12-162. BMC Gastroenterol. 2012. PMID: 23157720 Free PMC article. Clinical Trial.
Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study.
Puoti C, Barbarini G, Picardi A, Romano M, Pellicelli A, Barlattani A, Mecenate F, Guarisco R, Costanza OM, Spilabotti L, Bellis L, Bonaventura ME, Dell' Unto O, Elmo MG, Nicolini AM, Nosotti L, Soccorsi F; Club Epatologico Ospedaliero (Hospital Liver Club, CLEO). Puoti C, et al. Among authors: bonaventura me. J Viral Hepat. 2011 Jun;18(6):393-9. doi: 10.1111/j.1365-2893.2010.01319.x. J Viral Hepat. 2011. PMID: 20546499
Treatment of hepatitis C virus carriers with persistently normal alanine aminotransferase levels with peginterferon alpha-2a and ribavirin: a multicentric study.
Puoti C, Pellicelli AM, Romano M, Mecenate F, Guarisco R, Barbarini G, Mazzoni E, Spilabotti L, Bellis L, Paglia F, Barlattani A, Picardi A, Paffetti A, Bonaventura ME, Nosotti L, Mitidieri O, Dell'Unto O, Villani R, Dell'Unto C, Morrone A, Soccorsi F; Club Epatologico Ospedaliero (Hospital Liver Club - CLEO). Puoti C, et al. Among authors: bonaventura me. Liver Int. 2009 Nov;29(10):1479-84. doi: 10.1111/j.1478-3231.2009.02042.x. Epub 2009 Apr 28. Liver Int. 2009. PMID: 19422478
Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
Mecenate F, Pellicelli AM, Barbaro G, Romano M, Barlattani A, Mazzoni E, Bonaventura ME, Nosotti L, Arcuri P, Picardi A, Barbarini G, D'Ambrosio C, Paffetti A, Andreoli A, Soccorsi F; Club Epatologi Ospedalieri (CLEO) Group. Mecenate F, et al. Among authors: bonaventura me. BMC Gastroenterol. 2010 Feb 19;10:21. doi: 10.1186/1471-230X-10-21. BMC Gastroenterol. 2010. PMID: 20170514 Free PMC article. Clinical Trial.
Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.
Pellicelli AM, Vignally P, Messina V, Izzi A, Mazzoni E, Barlattani A, Bacca D, Romano M, Mecenate F, Stroffolini T, Furlan C, Picardi A, Gentilucci UV, Gulminetti R, Bonaventura ME, Villani R, D'Ambrosio C, Paffetti A, Mastropietro C, Marignani M, Fondacaro L, Cerasari G, Andreoli A, Barbarini G. Pellicelli AM, et al. Among authors: bonaventura me. Ann Hepatol. 2014 Jul-Aug;13(4):376-85. Ann Hepatol. 2014. PMID: 24927608 Free article.
Low risk of HCV infection in health care workers.
Di Nardo V, Bonaventura ME, Chiaretti B, Petrosillo N, Puro V, Ippolito G. Di Nardo V, et al. Among authors: bonaventura me. Infection. 1994 Mar-Apr;22(2):115. doi: 10.1007/BF01739019. Infection. 1994. PMID: 8070923 No abstract available.
"Side" effects of HAART: decreasing and changing occupational exposure to HIV-infected patients.
De Carli G, Puro V, Petrosillo N, Finzi G, Ferraresi I, Daglio M, Amoddeo C, Bombonato M, Bertucci R, Maccarrone S, Raineri G, Desperati M, Contegiacomo P, Penna C, Fulgheri M, Nelli M, Rebora M, Fasulo G, Bonaventura ME, Segata A, Marchegiano P, Mercurio V, Ippolito G; Studio Italiano Rischio Occupazionale da HIV (SIROH) Group. De Carli G, et al. Among authors: bonaventura me. J Biol Regul Homeost Agents. 2001 Jul-Sep;15(3):235-7. J Biol Regul Homeost Agents. 2001. PMID: 11693430
Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains.
Fabeni L, Berno G, Fokam J, Bertoli A, Alteri C, Gori C, Forbici F, Takou D, Vergori A, Zaccarelli M, Maffongelli G, Borghi V, Latini A, Pennica A, Mastroianni CM, Montella F, Mussini C, Andreoni M, Antinori A, Perno CF, Santoro MM; Resistance Study Group. Fabeni L, et al. J Clin Microbiol. 2017 Sep;55(9):2827-2837. doi: 10.1128/JCM.00656-17. Epub 2017 Jul 12. J Clin Microbiol. 2017. PMID: 28701420 Free PMC article.
12 results